Search Results

You are looking at 1 - 10 of 19 items for :

  • "Mycosis fungoides" x
  • User-accessible content x
Clear All
Full access

Steven M. Horwitz, Elise A. Olsen, Madeleine Duvic, Pierliugi Porcu and Youn H. Kim

. Willemze R Jaffe ES Burg G . WHO-EORTC classification for cutaneous lymphomas . Blood 2005 ; 105 : 3768 – 3785 . 3. Kim YH Liu HL Mraz-Gernhard S . Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical

Full access

Matthew Ulrickson, Fred Okuku, Victoria Walusansa, Oliver Press, Sam Kalungi, David Wu, Fred Kambugu, Corey Casper and Jackson Orem

Cutaneous T-cell lymphomas (CTCL) constitute 2% of all non-Hodgkin’s lymphoma diagnoses in the United States. The most common subtypes are mycosis fungoides (MF) and its leukemic presentation, Sézary syndrome (SS). 1 CTCLs were noted to occur

Full access

Neha Mehta-Shah, Steven M. Horwitz, Stephen Ansell, Weiyun Z. Ai, Jeffrey Barnes, Stefan K. Barta, Mark W. Clemens, Ahmet Dogan, Kristopher Fisher, Aaron M. Goodman, Gaurav Goyal, Joan Guitart, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric Jacobsen, Deepa Jagadeesh, Matthew A. Lunning, Amitkumar Mehta, Elise A. Olsen, Barbara Pro, Saurabh A. Rajguru, Satish Shanbhag, Aaron Shaver, Andrei Shustov, Lubomir Sokol, Pallawi Torka, Carlos Torres-Cabala, Ryan Wilcox, Basem M. William, Jasmine Zain, Mary A. Dwyer, Hema Sundar and Youn H. Kim

nodes, blood, and rarely visceral organs. 1 – 3 Mycosis fungoides (MF) is the most common subtype of CTCL and is usually associated with an indolent clinical course and intermittent, stable, or slow progression of the lesions. 4 Extracutaneous

Full access

Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center

Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B-lymphocytes, T-lymphocytes, or natural killer (NK) lymphocytes. An estimated 63,190 new cases of NHL, including 34,200 in men and 28,990 in women, will be diagnosed in 2007, and 18,660 deaths will occur. NHL is the fifth leading type of new cancer diagnosed and the ninth leading cause of cancer deaths among men and the seventh among women. The median age of individuals with NHL has risen in the past 2 decades, resulting in a patient population that may also have significant comorbid conditions, complicating treatment options. Important updates to these guidelines for 2008 include expanded second-line therapy options for patients with diffuse large B-cell lymphoma and those with peripheral T-cell lymphomas. In addition, the mycosis fungoides/Sézary syndrome section now includes pages on updated staging and classification systems and suggested treatment regimens.

For the most recent version of the guidelines, please visit

Full access

.0032 Review of the Treatment of Mycosis Fungoides and Sézary Syndrome: A Stage-Based Approach Horwitz Steven M. MD Olsen Elise A. MD Duvic Madeleine MD Porcu Pierliugi MD Kim Youn H. MD 04 2008 6 6 4 4 436 436 442 442

Full access

NHLs that also includes chronic lymphocytic leukemia, which was published earlier this year. NCCN Guidelines for Patients for Mycosis Fungoides is also expected to publish soon. “The goal of the NCCN Foundation is to deliver true insight to people

Full access

Sari M. Fien and Allan R. Oseroff

endogenous porphyrins . J Photochem Photobiol B 1989 ; 4 : 195 – 205 59. Paech V Lorenzen T Stoehr A . Remission of a cutaneous mycosis fungoides after topical 5-ALA sensitisation and photodynamic therapy in a patient with advanced HIV

Full access

Julie M. Vose

more recently addressed in the guidelines. Additional guidelines have been added over the past decade to assist in the treatment for patients with rare types of NHL, including HIV-associated NHL, mycosis fungoides, peripheral T-cell lymphoma, adult T

Full access

Andrew D. Zelenetz

algorithm for primary cutaneous CD30+ T-cell lymphoproliferative disorders is to distinguish them primarily from CD30+ transformed mycosis fungoides. The treatment for patients with LyP depends on the presence or absence of symptoms. Observation is preferred

Full access

Sophia Koo and Lindsey R. Baden

chemotherapy-refractory peripheral T-cell lymphomas . Blood 2004 ; 103 : 2920 – 2924 . 48. Lundin J Hagberg H Repp R . Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome